Impact of Malaria Control on Mortality and Anemia among Tanzanian Children Less than Five Years of Age, 1999–2010

Paul Smithson¹*, Lia Florey², S. Rene Salgado³, Christine L. Hershey³, Honorati Masanja¹, Achuyt Bhattarai⁴, Alex Mwita⁵, Peter D. McElroy⁴, Tanzania Malaria Impact Evaluation Research Group¶

¹Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania, ²ICF International, Rockville, Maryland, United States of America, ³United States Agency for International Development, U.S. President’s Malaria Initiative, Washington, DC, United States of America, ⁴Centers for Disease Control and Prevention, U.S. President’s Malaria Initiative, Atlanta, Georgia, United States of America, ⁵National Malaria Control Programme, Ministry of Health and Social Welfare, Dar es Salaam, United Republic of Tanzania

¶Membership of the Tanzania Malaria Impact Evaluation Research Group is provided in the Acknowledgments.

*psmithson@ihi.or.tz

Abstract

Background
Mainland Tanzania scaled up multiple malaria control interventions between 1999 and 2010. We evaluated whether, and to what extent, reductions in all-cause under-five child mortality (U5CM) tracked with malaria control intensification during this period.

Methods
Four nationally representative household surveys permitted trend analysis for malaria intervention coverage, severe anemia (hemoglobin < 8 g/dL) prevalence (SAP) among children 6–59 months, and U5CM rates stratified by background characteristics, age, and malaria endemicity. Prevalence of contextual factors (e.g., vaccination, nutrition) likely to influence U5CM were also assessed. Population attributable risk percentage (PAR%) estimates for malaria interventions and contextual factors that changed over time were used to estimate magnitude of impact on U5CM.

Results
Household ownership of insecticide-treated nets (ITNs) rose from near zero in 1999 to 64% (95% CI, 61.7–65.2) in 2010. Intermittent preventive treatment of malaria in pregnancy reached 26% (95% CI, 23.6–28.0) by 2010. Sulfadoxine-pyrimethamine replaced chloroquine in 2002 and artemisinin-based combination therapy was introduced in 2007. SAP among children 6–59 months declined 50% between 2005 (11.1%; 95% CI, 10.0–12.3%) and 2010 (5.5%; 95% CI, 4.7–6.4%) and U5CM declined by 45% between baseline (1995–9) and endpoint (2005–9), from 148 to 81 deaths/1000 live births, respectively.
Mortality declined 55% among children 1–23 months of age in higher malaria endemicity areas. A large reduction in U5CM was attributable to ITNs (PAR% = 11) with other malaria interventions adding further gains. Multiple contextual factors also contributed to survival gains.

**Conclusion**

Marked declines in U5CM occurred in Tanzania between 1999 and 2010 with high impact from ITNs and ACTs. High-risk children (1–24 months of age in high malaria endemicity) experienced the greatest declines in mortality and SAP. Malaria control should remain a policy priority to sustain and further accelerate progress in child survival.

**Introduction**

Malaria control in sub-Saharan Africa attained unprecedented momentum during the decade after 2000 [1–3]. Donor assistance for malaria control in Africa increased 10-fold between 2000 and 2010, from $200 million to nearly $2 billion annually [4]. Most support came after 2005 from national governments, the Global Fund to Fight AIDS, Tuberculosis and Malaria, the World Bank Booster Program, and the U.S. President’s Malaria Initiative. These resources permitted nationwide scale-up of highly effective malaria control interventions, including insecticide treated bednets (ITNs), indoor residual spraying (IRS) of household walls with insecticides, intermittent preventive treatment of malaria during pregnancy (IPTp), and artemisinin-based combination therapy (ACT) [4,5]. Numerous African countries are on track to meet the World Health Assembly target of a 75% reduction in malaria incidence by 2015 [2]. However, evaluations of the public health impact of malaria control at national scale are sparse [6–8].

At least 97% of the Tanzania population lived in areas with intense perennial malaria transmission in 2000 [9,10]. Over the following decade, funding for malaria control increased dramatically—from less than $1 million in 2000 to more than $30 million in 2006 and nearly $140 million in 2010—a cumulative investment of $452 million (S1A and S1B Fig). This funding facilitated the adoption and implementation of a series of malaria control policies and strategies (Fig 1) [11,12]. Social marketing of ITNs and insecticide treatment kits began in 2000 [13]. A year later, high levels of chloroquine resistance prompted a shift to sulfadoxine-pyrimethamine (SP) as first-line therapy for uncomplicated malaria [14,15]. In 2002, NMCP’s first Medium-term Strategic Plan 2002–7 was implemented and IPTp using SP was adopted to control malaria in pregnancy. Large-scale ITN distribution began with the Tanzania National Voucher Scheme targeted to pregnant women [16] in 2004 and then infants in 2007 [17]. A second Medium-term Strategic Plan 2008–13 called for an ACT (artemether-lumefantrine) as first-line therapy (from 2007), RDTs at peripheral health facilities (from 2009), and a target of 80% ITN coverage by 2010. Distribution of 8.6 million free long-lasting insecticidal nets (LLINs) to all children less than five years of age began in 2009 and was completed in 2010 [18]. Later that year a universal coverage campaign began to distribute 18 million free LLINs to cover all remaining sleeping spaces [19]. IRS was implemented in Kagera beginning in 2007, and advanced to Mwanza and Mara (three of the original 21 administrative regions) by 2010, but covered only 6% of the national population.

By 2010 malaria intervention coverage had been brought to levels where an impact may reasonably be expected. After a decade of stagnation, all-cause under-five child mortality (U5CM)
declines were already evident by 2005 [20], and current UNICEF data indicate Tanzania likely achieved their Millennium Development Goal 4 (MDG4) target of a two-thirds reduction in U5CM between 1990 and 2015: modeled rates of U5CM declined from 166 to 132 to 54 deaths per 1000 live births in 1990, 2000, and 2012, respectively (a 68% decline) [21].

The Roll Back Malaria (RBM) Partnership’s Monitoring and Evaluation Reference Group (MERG) recommends U5CM as the primary indicator of malaria control impact [22]. This recommendation is based on our: 1) inability to measure malaria-specific mortality in most developing countries, 2) expectation that rapid scale-up of interventions to high levels will result in measurable declines in U5CM, and 3) recognition that malaria has a substantial indirect effect on mortality that will be captured in U5CM estimates [23]. The MERG approach assumes that a portion of the declining trends in U5CM can be plausibly attributed to malaria control efforts if improvements in population-level measurements are found in steps along the causal pathway (e.g., increased ITN coverage and reduced severe anemia prevalence) [24]. As U5CM rates and severe anemia prevalence decline at an accelerated pace, preceded by rapid scale-up of intervention coverage, the conclusion that malaria control efforts reduced malaria-specific mortality becomes more plausible. This plausibility is strengthened if trends in other contextual factors (e.g., immunization, micronutrient supplementation, climate) affecting mortality did not appreciably change during the same period.

Our objective was a summative evaluation to determine if Tanzania’s scale-up of malaria interventions during 1999–2010 helped accelerate declines in malaria morbidity (particularly severe anemia, a common manifestation of Plasmodium falciparum infection in high transmission areas [25,26]) and U5CM. The evaluation is restricted to Tanzania Mainland since Zanzibar has a separate Ministry of Health and its National Malaria Control Program followed a different trajectory.

**Methods**

All surveys were approved by the ethical review board of Tanzania’s National Institute for Medical Research and ICF International’s institutional review board. Verbal informed consent was sought from all survey respondents, with an informed consent statement signed by each survey interviewer. All analyses were performed on anonymized and de-identified datasets.
Evaluation design

Our overall evaluation design embraced both adequacy and plausibility aspects (Fig 2) [24]. Our initial adequacy assessment examined temporal trends in malaria intervention coverage and whether declines in severe anemia prevalence (SAP) and U5CM were observed. This step also explored inequities in malaria intervention coverage across four basic demographic characteristics and whether the same inequities existed for SAP and U5CM rates. Adequacy assessments lack comparison groups and do not address non-malarial contextual factors thought to affect the impact indicators of interest [24]. The plausibility assessment included a series of analyses to complement the adequacy assessment and garner greater confidence that a portion of the reductions in SAP and U5CM were due to malaria intervention scale-up [27]. The plausibility assessment stems from Hill’s specificity criteria [28]. This effort contributed to the consistency and specificity of our plausibility assessment. We assessed whether malaria control led to more accelerated declines in SAP and U5CM in younger (<23 months) versus older (24–59 months) children, and among those living in higher versus lower areas of malaria endemicity. Trends in prevalence of other contextual factors with recognized potential to contribute alternative explanations for changes in U5CM were explored. Finally, we examined whether the increase in malaria intervention coverage was compatible with the timing and magnitude of reductions in SAP and U5CM, while also considering changes in relevant contextual factors.

Data sources and indicators

Malaria intervention coverage, malaria parasitemia, SAP, all-cause mortality, demographic characteristics, and coverage of other health interventions were obtained from four, nationally-representative household surveys in 1999, 2004/5, 2007/8, and 2010 that included 2747, 7847, 6332 and 7720 mainland households, respectively [29–32]. Each survey included a sampling design that was 100% inclusive of all 20 regions, plus Dar es Salaam. All surveys occurred
during the drier season (Sep-Feb), but fieldwork for the 2010 survey extended three months longer. Malaria intervention coverage was measured using six standard RBM indicators [33] including the proportion of: households that owned at least one ITN; children <5 years of age, pregnant women, and de facto survey population who slept under an ITN the night before the survey; women who received IPTp-2 for pregnancies within the past two years; and children <5 years of age with fever in the past two weeks who received treatment with a first-line antimalarial the same or next day after fever onset. Capillary blood specimens were obtained via finger or heel prick from children 6–59 months of age who slept in each household the night before the survey. Hemoglobin (Hb) concentration was measured (HemoCue® instrument) and severe anemia defined as Hb < 8.0 g/dL, adjusted for altitude [34,35]. A histidine-rich protein 2-based RDT (Paracheck®) detected P. falciparum parasitemia (2007/8 survey only).

Contextual factors (socio-economic, maternal and reproductive health, nutrition, immunization, other morbidities) were sourced from the same surveys described above [29–32]. Additional published sources are cited for trends in rainfall, growth in gross domestic product (GDP) [36], and HIV/AIDS indicators [37–39]. Rainfall data (1983–2010) were obtained from approximately 200 ground-based stations of the Tanzania National Meteorological Agency. Minimum/maximum temperatures were generated by combining weather station measurements with NASA’s land surface temperature estimates with a digital elevation model.

Analyses

**Trends in intervention coverage, SAP and U5CM.** For each survey, RBM core coverage indicators were calculated with corresponding 95% confidence intervals (CIs) using standard errors corrected for multi-stage survey design [34]. SAP estimates with 95% CIs were calculated for children 6–59 months of age. Direct estimates of U5CM and 95% CIs were calculated with the synthetic cohort life table approach using birth histories over 0–4 years prior to each survey. A chi-square test for linear trend in proportions assessed changes in intervention coverage, SAP and U5CM. ITN use, SAP, and U5CM were further stratified by four key demographic characteristics including sex (male/female), residence (urban/rural), wealth quintile, maternal education (none, primary incomplete, primary complete, secondary+) and plotted with corresponding 95% CIs to assess trends in equity. Under-five, infant, and neonatal mortality rates with 95% CIs were plotted to reflect temporal trends from pre-baseline [40,41] through endpoint.

**Plausibility assessment (1): Temporal trends by age.** Malaria morbidity and mortality are highly age-dependent, with younger children (<24 months) at greater risk for both outcomes, particularly in areas with higher intensity P. falciparum transmission [42–44]. SAP was stratified by age (6–23 and 24–59 months). Further mortality analyses excluded neonatal deaths since a minimal proportion of these deaths were likely attributable to malaria [45]. Thus all-cause mortality was dichotomized at 1–23 and 24–59 months of age.

**Plausibility assessment (2): Temporal trends by malaria endemicity.** SAP and mortality rates were stratified by level of malaria endemicity to assess whether greater impact was observed in higher endemicity areas. Tanzania mainland regions were divided into three endemicity categories: "lower” (7 regions, prevalence 0–9.2%), “moderate” (7 regions, prevalence 10.4–21.9%), and “higher” (6 regions, prevalence 28.7–32.6%) using region-specific P. falciparum prevalence from 2007/8 (the only national survey to include this indicator). Survey-specific adjusted odd ratios (ORs) for severe anemia and rate ratios (RRs) for all-cause mortality were obtained using logistic and Cox proportional hazards regression models, respectively, to control for the four key demographic characteristics described above, malaria endemicity level, and age (logistic model only).
Plausibility assessment (3): Temporal trends by age and malaria endemicity combined. Age and malaria endemicity exhibited differential risk for SAP and all-cause child mortality. Trends in these outcomes were assessed separately for children 1–23 months of age and children 24–59 months of age, stratified by endemicity.

Plausibility assessment (4): Accounting for contextual factors. Climate data were examined in a three-step analysis (IRI Report, supplemental online material). The Climate Suitability for Malaria Transmission Tool [46] was first used to estimate the number of months during the year when climatological conditions were suitable for malaria transmission. A Weighted Anomaly of Standardized Precipitation (WASP) Tool [47,48] estimated the change in rainfall over the evaluation period relative to baseline (1995–99). WASP and temperature data were combined to assess whether the prevailing climate in Tanzania was suitable for malaria transmission relative to baseline. The Climate Analysis Tool explored annual precipitation and temperature data according to temporal and spatial factors affecting malaria transmission. Change in per capita GDP (constant prices) was expressed as cumulative change between 1995–1999 and 2005–2009. For all other contextual factors, baseline (1999) and endpoint (2010) values with 95% CIs and percent changes (relative) were obtained. Differences in baseline and endpoint values were assessed with a Z-test using the standard errors in the Z-score formula. For a small subset of factors lacking 1999 and 2010 values (e.g., HIV/AIDS indicators) the earliest and latest available estimates were used for baseline and endpoint.

Plausibility assessment (5): Magnitude of reductions in all-cause mortality. We derived the attributable changes in U5CM due to the observed increases in malaria intervention coverage between 1999 and 2010 and for contextual factors with significant change over the same period. These reductions were derived using population attributable risk percentage (PAR%) calculations based on prevalence of exposure (E) and non-exposure (Ē) to each factor in 1999 and 2010, respectively, and published estimates of relative risk (RR) for all-cause mortality associated with that exposure factor [49–59]. The published RR estimate for effective first-line antimalarials (specifically ACTs) used malaria-specific mortality rather than all-cause mortality. The unadjusted PAR% is useful for comparing the crude marginal effects of multiple interventions and was calculated as:

$$PAR\% = \frac{\bar{E}_{2010} + RR(E_{2010}) - [\bar{E}_{1999} + RR(E_{1999})]}{\bar{E}_{1999} + RR(E_{1999})}$$

It is an estimate of how the change in prevalence of each risk factor (intervention or exposure) and known strength of the association with mortality resulted in either increases or decreases in rates of U5CM. The PAR% provides an informative link between causality and public health action [61,62].

Results

Adequacy assessment: Trends in intervention coverage and rates of SAP and U5CM

Malaria intervention coverage generally improved between 1999 and 2010 (Table 1). Household ownership of ITNs and ITN use by children less than 5 years of age, pregnant women, and the de facto population as a whole increased by 61, 62, 55, and approximately 45 percentage points, respectively. A marked increase in ITN coverage between 2007/8 and 2010 followed the distribution of 18 million free ITNs to children less than 5 years of age (May 2009–May 2010). The proportion of pregnant women who received at least two doses of SP for IPTp increased from 21% in 2005 to 26% in 2010 (p<0.0001). During 1999–2010, a high percentage (53% in 1999 and 60% in 2010) of children with fever in the two weeks preceding the
Table 1. Trends in malaria intervention coverage indicators, Mainland Tanzania, 1999–2010.

| Variable†† | 1999 % (95% CI) N | 2004/5 % (95% CI) N | 2007/8 % (95% CI) N | 2010 % (95% CI) N | Change (abs.) * | p † |
|------------|------------------|---------------------|---------------------|------------------|----------------|-----|
| **Nets**   |                  |                     |                     |                  |                |     |
| Household ownership ≥1 | 29.8 (25.6–34.3) 3,526 | 45.9 (43.1–48.6) 9,483 | 55.6 (52.9–58.2) 8,269 | 74.7 (72.8–76.4) 9,377 | 44.9 | <0.0001 |
| ITNs       |                  |                     |                     |                  |                |     |
| Household ownership ≥1 | -2.4 (20.5–24.6) 3,526 | 22.5 (36.1–40.6) 9,483 | 38.3 (61.7–65.2) 8,269 | 63.5 (61.2–66.5) 9,377 | 61.1 | <0.0001 |
| Use (children <5 yrs) | -1.7 (1.2–2.8) 3495 | 15.8 (22.6–27.2) 8,147 | 24.8 (61.7–65.2) 7,319 | 63.9 (61.2–66.5) 7,768 | 62.2 | <0.0001 |
| Use (pregnant women) | -1.9 (0.8–4.6) 369 | 15.7 (12.9–19.1) 1,054 | 26.0 (21.7–30.9) 823 | 57.1 (52.4–61.6) 922 | 55.2 | <0.001 |
| Use (all persons) | n/a** (13.3–16.7) 44,830 | 14.9 (17.8–21.6) 40,660 | 19.7 (12.9–19.1) 45,125 | 45.1 (52.4–61.6) 45,125 | -45 | <0.0005 |
| **IPTp during last pregnancy** |                  |                     |                     |                  |                |     |
| 2+ doses   | n/a (19.0–22.7) | 20.8 (27.0–32.3) 3,415 | 29.6 (23.6–28.0) 2,969 | 25.7 (23.8–29.0) 3,179 | 25.7 | <0.0001 |
| 1+ dose    | n/a (47.1–53.1) | 50.1 (53.5–60.3) 3,415 | 56.9 (56.8–62.9) 2,969 | 59.9 (56.7–63.4) 3,179 | 59.9 | <0.0001 |
| **Malaria treatment** |                  |                     |                     |                  |                |     |
| Any antimalarial (timing not considered) | 53.0 (45.2–60.6) 988 | 58.2 (54.7–61.5) 1,882 | 57.0 (52.4–61.6) 1,320 | 60.1 (56.7–63.4) 1,715 | 7.1 | 0.2347 |
| Recommended first-line (same or next day) ‡ | n/a (18.7–24.2) | 21.4 (11.6–17.2) 1,882 | 14.2 (23.8–29.8) 1,320 | 26.7 (23.8–29.8) 1,715 | 5.3‡ | 0.0002 |

* Percent absolute change, earliest value vs. 2010
† P-value obtained from chi² test for linear trend in proportions across the four surveys (trend test begins with 2004/5 for indicators with “n/a” in 1999)
‡ First-line therapy in 1999: chloroquine; 2004/5: sulfadoxine/pyrimethamine; 2007/8 and 2010: ACT
** No ITN indicators were obtained in the 1999 (baseline) survey since these indicators were only developed and promoted by RBM after 2002. Consequently, the 1999 survey questionnaire did not include a full roster of nets, net treatment and use. All families were questioned about the number of nets they owned and the number of children <5 years of age per household was recorded, but net treatment (soaking in insecticidal solution) was asked only for households with children <5 years of age where some or all children slept under nets. The data available permitted a precise estimate of household net ownership; a fairly precise estimate of net and ITN use by children under five, and an estimate of household ITN ownership using available data on proportion of nets that were treated.
†† N in the table represents weighted denominator (number of households, children under 5 years of age, pregnant women, all persons, or febrile children under 5 years of age) for each variable shown

doi:10.1371/journal.pone.0141112.t001
household survey received antimalarial treatment. The percentage of children who received a first-line antimalarial the same or next day following fever onset did not exceed 27% and showed no consistent trend.

SAP among children 6–59 months of age declined 50%: from 11.1% (95% CI, 10.0–12.3%) in 2004/5, to 7.5% (95% CI, 6.6–8.6%) in 2007/8, and 5.5% (95% CI, 4.7–6.4%) in 2010 (trend \( p < 0.0001 \)). USCM rates declined 45%: from 148 (95% CI; 129–166) deaths per 1000 live births in 1999, to 112 (95% CI, 103–122) in 2004/5, to 92 (95% CI, 83–101) in 2007/8, and 81 (95% CI, 72–90) in 2010 (trend \( p < 0.0001 \)); a decline of 67 deaths per 1,000 live births relative to baseline. Much of the decline in U5CM was due to a 49% reduction in infant mortality rate, but with no significant improvement in neonatal mortality (Fig 3): rates remained relatively unchanged across pre-baseline periods: 1987–91, 1991–5, and 1995–99.

Stratification by demographic characteristics revealed trends in ITN use among children less than 5 years of age, SAP, and U5CM associated with residence, wealth, and maternal education, but not sex. In the earlier surveys, ITN use was lower (S2A Fig) and SAP (S2B Fig) and mortality rates (S2C Fig) were higher among rural children, among children from poorer households, and among children with less educated mothers. These disparities disappeared by 2010. Small numbers in the malaria treatment categories precluded analysis of trends by residence, wealth, and maternal education.

Plausibility assessment (1 and 2): SAP and all-cause mortality declined faster among youngest children and those residing in higher endemicity areas

In 2004/5, the SAP among children 6–23 months of age (17.1%) was over twice as high than in children 24–59 months of age (7.8%) (adjusted OR = 2.5, 95% CI 2.1–2.9). Subsequently, age-stratified SAP estimates improved over time, with a more accelerated decline among children 6–23 months (Fig 4A). In 2004/5, SAP was greater among children in the higher (15.8%) and moderate (10.3%) endemicity strata as compared to children in the lower (6.5%, referent) stratum (adjusted OR = 2.4, 95% CI 1.8–3.2 and OR = 1.5, 95% CI 1.1–2.0, respectively). By 2010, declines in SAP in the higher and moderate endemicity areas were at least twice as great as the declines in lower endemicity (Fig 4C). Notably, the disparity in SAP across endemicity levels was less pronounced in 2007/8, and by 2010 no differences were detected (adjusted OR = 1.4,
95% CI 0.9–2.2 and OR = 1.3, 95% CI 0.8–2.1 for higher and moderate endemicity, respectively).

Children 1–23 months of age experienced a more accelerated decline in mortality rate over time (from 78 to 35 deaths per 1000 live births) as compared to 24–59 month old children (from 28 to 19 deaths per 1000 live births) (Fig 4B).

In 1999, mortality was higher in children from higher endemicity compared to lower endemicity areas (adjusted RR = 1.4, 95% CI 1.1–1.8), but not in those from moderate endemicity areas (adjusted RR = 1.1, 95% CI 0.9–1.6). These all-cause mortality trends in children 1–59 months of age also declined markedly across endemicity (Fig 4D), with greater declines among children from the higher and moderate endemicity areas in a pattern similar to the SAP analysis. Mortality risk in 2004/5 remained greater in the higher (adjusted RR = 1.4, 95% CI 1.2–1.7) and moderate (adjusted RR = 1.4, 95% CI 1.2–1.7) endemicity groups. By 2010, mortality in the higher endemicity stratum still remained greater (RR = 1.7, 95% CI 1.3–2.1), but rates in the moderate and lower strata had converged. Overall, a more accelerated decline in all-cause mortality among 1–59 months of age occurred between 2000 and 2010 in the higher and moderate endemicity areas (reductions of 70 and 100 deaths per 1000 live births, respectively) as compared to the lower endemicity areas (reduction of 38 deaths per 1000 live births).

Plausibility assessment (3): SAP and all-cause mortality declined even faster among younger children residing in higher endemicity

Reductions in SAP over time were more evident upon combined stratification by age and endemicity (Table 2). In 2004/5, SAP among 6–23 month old children from low, medium, and high endemicity (8.5%, 13.5%, and 20.5%, respectively) were generally twice as high as the endemicity-specific estimates (4.9%, 7.1%, and 11.0% respectively) among the 24–59 month old children. The overall reduction of SAP was most pronounced for the 6–23 month age group living in higher endemicity areas where SAP declined 67% between 2004/5 and 2010 (from 20.5% to 7.9%).
When mortality rates were stratified by both age and endemicity (Table 3), only the 1–23 month age group showed a significant decline across the evaluation period (trend \( p < 0.0001 \)). The largest mortality declines occurred among children aged 1–23 months living in areas of moderate and higher malaria endemicity (65.7% and 54.7% relative declines, respectively). No significant declines in mortality were detected for the 24–59 month age group within the three endemicity strata.

Plausibility assessment (4): Changes in some contextual factors also influenced U5CM.

Table 2 includes baseline and endpoint prevalence estimates (or medians where appropriate) for health-related contextual factors thought to influence U5CM.

| Endemicity (6–23 mo.) | 2004/5 % (95% CI) N | 2007/8 % (95% CI) N | 2010 % (95% CI) N | Change (abs.) \( \dagger \) | \( p \dagger \) |
|-----------------------|---------------------|---------------------|-------------------|-----------------|-------|
| Lower                 | 8.5 (6.5–11.1) 8.59 | 5.8 (3.8–8.7) 701  | 6.4 (4.4–9.2) 596 | -2.1            | 0.0062 |
| Moderate              | 13.5 (11.2–16.0) 22 | 14.8 (11.8–18.6) 944 | 9.4 (6.1–14.2) 754 | -4.1            | <0.0001 |
| Higher                | 20.5 (17.3–24.0) 15 | 14.4 (11.3–18.1) 1,269 | 7.9 (5.8–10.6) 837 | -12.6           | <0.0001 |

| Endemicity (24–59 mo.) | 2004/5 % (95% CI) N | 2007/8 % (95% CI) N | 2010 % (95% CI) N | Change (abs.) \( \dagger \) | \( p \dagger \) |
|-----------------------|---------------------|---------------------|-------------------|-----------------|-------|
| Lower                 | 4.9 (3.5–6.83) 1,604 | 2.0 (1.3–3.2) 1,327 | 3.2 (2.1–5.0) 1,190 | -1.7            | 0.0084 |
| Moderate              | 7.1 (5.7–8.8) 1,289 | 6.0 (4.6–7.8) 1,171 | 3.4 (2.5–4.5) 1,512 | -3.7            | 0.0001 |
| Higher                | 11.0 (9.0–13.3) 1,713 | 7.5 (5.6–10.0) 1,584 | 5.8 (4.4–7.6) 1,620 | -5.2            | <0.0001 |

* Endemicity categories: lower = 0–9.2%; moderate = 10.4–21.9%; higher = 28.7–32.6%
\( \dagger \) Percentage points absolute change, earliest value vs. 2010
\( \dagger \) P-value obtained from chi\(^2\) test for linear trend in proportions across the three surveys

doi:10.1371/journal.pone.0141112.t002

When mortality rates were stratified by both age and endemicity (Table 3), only the 1–23 month age group showed a significant decline across the evaluation period (trend \( p < 0.0001 \)). The largest mortality declines occurred among children aged 1–23 months living in areas of moderate and higher malaria endemicity (65.7% and 54.7% relative declines, respectively). No significant declines in mortality were detected for the 24–59 month age group within the three endemicity strata.

Plausibility assessment (4): Changes in some contextual factors also influenced U5CM.

Table 4 includes baseline and endpoint prevalence estimates (or medians where appropriate) for health-related contextual factors thought to influence U5CM.

Climate. The 12-month WASP trend over the period 1985–2010 revealed conditions were generally drier than the long-term average after 1999 (S3 Fig). The period over which baseline mortality was measured (1995–9) included a major El Niño year (1997–8). By contrast every year after 1999 was drier than the long-term average, with the exception of 2006–7. Evidence of significant warming (~ 0.3°C per decade) in many regions of Tanzania was detected.

Socio-economic factors. At the national level, per capita GDP was 47% higher in 2005–09 compared to 1995–9. The mean years of schooling among 15–49 year old females increased by 1.0 year between 1999 and 2010. The proportion of households with access to an improved
water source declined, but the proportion with modern floor and roof materials increased. The proportion of households with a toilet or frequent problems in satisfying food needs did not change.

Maternal and reproductive health factors. There was no significant change in the proportion of births falling in the “high fertility risk” category, nor in the likelihood of low birth weight or facility-based delivery. The proportion of women making at least four antenatal visits during their last pregnancy declined 39% over the evaluation period, but cumulative doses of neonatal tetanus toxoid (NNT) remained high. The maternal mortality ratio in Tanzania declined 37% over the evaluation period, from 730 (95% CI, not available) to 578 (95% CI, 466–690) to 454 (95% CI, 353–556) per 100,000 live births for the 10-year period preceding the 2000, 2004/5 and 2010 surveys, respectively.

Nutrition. The median duration of exclusive breastfeeding rose from 1.1 to 2.4 months. Anthropometric indices (stunting and underweight) showed significant improvements of six and nine percentage points, respectively. Vitamin A supplementation for children aged 6–59 months rose more than four-fold between 1999 and 2010, from 13% to 60%.

Vaccination. Child vaccination coverage indicators did not change significantly between baseline and 2010. Antigens for hepatitis B and *H. influenzae* type B (Hib) were added to the diptheria/pertussis/tetanus (DPT) regimen in 2002 and 2009, respectively. The probability of seeking healthcare at a health facility by children aged 0–59 months who suffered cough, fever, or diarrhea did not change.

Other morbidity. The proportion of children with fever reported in the two weeks prior to the survey declined by one-third from 35% to 23%. Two-week prevalence of suspected acute respiratory infection (ARI: cough with rapid breathing) declined by nearly half (14% to 8%), but with no change in diarrhea prevalence (~13%).

HIV/AIDS. Adult HIV prevalence declined over the decade, from 7.0% to 5.3%. HIV prevalence among females (15–49) did not change between 2003 and 2007 (one percentage
### Table 4. Prevalence (%) of contextual variables recognized to influence all-cause mortality over time in Mainland Tanzania, 1999 versus 2010.

|          | 1999 value (95% CI) | N | 2010 value (95% CI) | N | Δ (%) | p     |
|----------|---------------------|---|---------------------|---|-------|-------|
| **Socio-economic** |                      |    |                      |    |       |       |
| Real GDP% change (1999 = 100) | 100               | -  | 147                 | -  | 47%   | na    |
| Women (15-49y) yrs of ed. (mean) | 4.7               | 3,929 | 5.7                 | 9,813 | 21%   | <0.0005 |
| Improved water source¹ | 65.8              | 3,526 | 56.9                 | 9,377 | -14%  | 0.016 |
| Households with toilet² | 88.8              | 3,526 | 86.3                 | 9,377 | -3%   | 0.17  |
| Modern floor material³ | 20.9              | 3,526 | 31.8                 | 9,377 | 52%   | <0.0005 |
| Modern roof material⁴ | 50.6              | 9,483 | 61.9                 | 9,377 | 22%   | <0.0005 |
| Problem satisfying food needs⁵ | 22.6              | 9,483 | 23.3                 | 9,377 | 3%    | 0.54039 |
| **Maternal & reproductive** |                      |    |                      |    |       |       |
| Births any high-risk fertility category⁶ | 56.9              | 3,196 | 57.1                 | 7,955 | 0%    | 0.916 |
| ANC visits 4+ | 69.9              | 2,131 | 42.7                 | 5,378 | -39%  | <0.0005 |
| Last pregnancy protected against NNT⁷ | 81.0              | 5,378 | 88.2                 | 1,533 | 9%    |       |
| Delivery at a health facility | 43.7              | 3,196 | 50.2                 | 7,955 | 15%   | 0.067 |
| Low birth weight <2500g (%) | 8.4               | 772  | 6.1                  | 2,786 | -27%  | 0.096 |
| Female HIV prevalence (15-49y)⁸ | 7.7               | 5,753 | 6.8                  | 7,909 | -12%  | na    |
| **Nutrition** |                      |    |                      |    |       |       |
| Median duration exclusive breastfeed (mo) | 1.1               | 326  | 2.4                  | 818  | 118%  |       |
| Under-fives stunted (%)⁹ | 44.0              | 2,746 | 35.7                 | 7,265 | -13%  | 0.003 |
| Under-fives underweight (%)¹⁰ | 29.5              | 2,746 | 20.5                 | 7,265 | -31%  | <0.0005 |
| Vitamin A supplementation (6-59mo)¹¹ | 13.3              | 2,503 | 59.8                 | 6,638 | 350%  | <0.0005 |
| **Vaccination** |                      |    |                      |    |       |       |
| BCG | 92.6              | 578  | 95.4                 | 1,533 | 3%    | 0.13  |
| DPT3 / DPT3-HB-Hib | 80.9              | 578  | 87.8                 | 1,533 | 9%    | 0.064 |
| Polio3 | 79.9              | 578  | 84.9                 | 1,533 | 6%    | 0.112 |
| Measles | 78.2              | 578  | 84.5                 | 1,533 | 8%    | 0.061 |
| All (BCG, measles, DPT3, polio3) | 68.3              | 578  | 75.1                 | 1,533 | 10%   | 0.077 |
| **Health Care Access** |                      |    |                      |    |       |       |
| Health care utilisation¹² | 70.1              | 1,399 | 68.6                 | 2,776 | -2%   | 0.669 |
| **Morbidity (past 2 weeks)** |                      |    |                      |    |       |       |
| Fever | 35.3              | 2,792 | 23.2                 | 7,388 | -35%  | <0.0005 |
| Suspected ARI¹³ | 13.8              | 2,820 | 7.7                  | 7,461 | -44%  | <0.0005 |
| Diarrhoea | 12.4              | 2,820 | 14.6                 | 7,461 | 18%   | 0.06  |
| Any¹⁴ | 49.6              | 2,820 | 37.2                 | 7,461 | -25%  | <0.0005 |
| **HIV/AIDS (UNAIDS 2011 and 2013)**¹⁰⁹,¹¹⁰ |                      |    |                      |    |       |       |
| Adult (male/female) HIV prevalence (15-49yrs) | 7.0               | 6.3–7.8 | 5.3                 | 4.8–5.8 |
| Female HIV prevalence (15–49 yrs) | 7.7               | 6.8–8.6 | 6.3                 | 5.7–7.0 |
| Pregnant women tested for HIV | <1%               | n/a   | 86                  | —     |       |
| Pregnant women HIV prevalence | 5.3               | —     | —                  | —     |       |
| Eligible ARV coverage (all age)¹⁵ | <1%               | n/a   | 42                  | 39–46 |
| Eligible children (<15 y) ARV coverage | <1%               | n/a   | 18                 | 16–21 |
| HIV-infected PW recv ARV for PMTCT | <1%               | n/a   | 59                 | 52–68 |

(Continued)
1. HIV-exposed infants received ARV for PMTCT: In 1999, only 1% of HIV-exposed infants received ARVs for PMTCT, compared to 68% in 2010. The number of infants receiving ARVs increased from 59 to 77, reflecting a significant improvement in PMTCT services.

2. Plausibility assessment (5): Magnitude & direction of expected changes in U5CM

Malaria interventions and several other contextual factors contributed to reductions/increases in U5CM (Table 5). Among the malaria interventions scaled-up nationally, the greatest reduction in U5CM was attributable to ITN use among children less than 5 years of age, with a PAR% of 11%. Improvement in ITN use among pregnant women and IPTp (at least two doses) both contributed to reductions, but only in the neonatal period (based upon published efficacy estimates for these interventions). Our derived RR for malaria-specific mortality associated with prompt access to effective first-line antimalarials yielded a PAR% of 18%.

Among the multiple contextual factors with significant change between 1999 and 2010, at least six would be expected to result in declines in U5CM, ranging from 3% (PMTCT coverage improvement and declines in prevalence of stunting) to 10% (vitamin A supplementation improvement based on published estimates of RR). Likewise, declines in four or more antenatal care (ANC) visits over the evaluation period were associated with mortality increases (PAR% = 11%), but mostly through neonatal deaths. These factors are not expected to be entirely independent of one another so that the individual impact magnitude cannot simply be summed. Nonetheless, this analysis serves to compare the expected impact of increased malaria intervention coverage as compared to the anticipated effect of changes in multiple other contextual factors unrelated to malaria control.
This impact evaluation provides plausible evidence that a 45% reduction in U5CM in Tanzania was partially attributable to dramatic reductions in SAP following increased funding and adoption of sound policies to guide the scale-up of multiple malaria interventions during the period 1999 to 2010. Younger age children (excluding neonates) from areas of higher malaria endemicity experienced the greatest declines in all-cause mortality and SAP (55% and 67%, respectively). Numerous other contextual factors associated with U5CM also improved over the evaluation period and likely contributed to declines in mortality. However, few of these factors contributed the same magnitude of mortality reduction as the combined malaria interventions. Our PAR% analysis illustrates how malaria control interventions contributed to the 45% decline in U5CM in Tanzania between 1999 and 2010, with 11% of this overall reduction attributable to ITNs alone. ITN use among Tanzanian children less than five years of age reached 64% by 2010, and further gains in child survival will be achieved with recent increases in ITN coverage.

After a decade (1990s) of stagnation in child survival in Tanzania, the decline in U5CM (1999–2010) was almost certainly a consequence of reductions in malaria-specific mortality associated with the 50% decline in SAP. The age and endemicity stratifications for SAP and mortality exhibited a pattern of change consistent and specific to observed malaria risk, with declines most pronounced in the more vulnerable children aged 1–23 months in areas of higher malaria endemicity [42,64]. ITN coverage improved slowly between 2000 and 2007/8, and then increased abruptly by 2010. At time of the 2010 survey, children less than 24 months of age had benefited from this protection, helping to further accelerate mortality declines in this age group. While low IPTp coverage likely had only minimal impact

### Table 5. Coverage estimates of important child survival interventions and corresponding relative risk estimates with predicted proportions of all-cause under-5 mortality averted (or increased) in Mainland Tanzania, 1999–2010.

| Intervention/risk factor | 1999 (baseline) | 2010 (endpoint) | Published effect estimate RR (95% CI) | Decrease/increase in U5 mortality (PAR%) | Source†† |
|--------------------------|-----------------|-----------------|--------------------------------------|------------------------------------------|---------|
| **Malaria Interventions** |                 |                 |                                      |                                          |         |
| ITN use <5yrs            | <2%             | 64%             | 0.82 (0.75–0.90)                     | -11% (1–59 mo)                           | [49]    |
| ITN use pregnant women   | <2%             | 57%             | 0.84 (0.76–0.93)                     | - 9% (neonatal)                          | [50,51] |
| IPTp-2+                  | 0%              | 26%             | 0.80 (0.71–0.91)                     | - 5% (neonatal)                          | [50]    |
| Effective 1st line therapy* | 10%           | 27%             | 0.02 (0.01–0.14)                     | - 18% (malaria-specific, 1–59 mo)        | [52]    |
| **Other contextual factors** |                 |                 |                                      |                                          |         |
| Female education (median) | 4.7 y           | 5.7 y           | 0.50                                 | - 8%                                     | [53]    |
| ANC visits 4+            | 70%             | 43%             | 0.68 (0.59–0.79)                     | + 11% (neonatal)                         | [54]    |
| PMTCT†                   | <1%             | 4%              | 0.57                                 | - 3%                                     | [55]    |
| Exclusively breastfed <6 mo. | 32%         | 50%             | 0.41 (0.24–0.69)                     | - 8% (<6 mo)                             | [56]    |
| Stunted‡                 | 44%             | 36%             | 1.47 (1.21–1.78)                     | -3%                                      | [57]    |
| Underweight**            | 30%             | 21%             | 2.49 (1.56–3.97)                     | -9%                                      | [57]    |
| Vitamin A supplementation | 13%             | 60%             | 0.76 (0.69–0.83)                     | - 10%                                    | [58,59] |

* 1999 exposure estimate assumes half of febrile children seeking treatment received ineffective therapy due to *P. falciparum* reduced susceptibility to chloroquine. Artemisinin-based combination therapy relative risk based on malaria-specific mortality reduction in ACT efficacy trials.
† Prevention of mother-to-child transmission (PMTCT) of HIV infection. Figures represent proportion of all pregnant women (HIV infected and uninfected) receiving PMTCT.
‡ Height-for-age is below -2 SD from the median of the NCHS/CDC/WHO international reference population.
** Weight-for-age is below -2 SD from the median of the NCHS/CDC/WHO international reference population.
†† Sources for RR estimates represent meta-analyses or multi-country studies.

Discussion

This impact evaluation provides plausible evidence that a 45% reduction in U5CM in Tanzania was partially attributable to dramatic reductions in SAP following increased funding and adoption of sound policies to guide the scale-up of multiple malaria interventions during the period 1999 to 2010. Younger age children (excluding neonates) from areas of higher malaria endemicity experienced the greatest declines in all-cause mortality and SAP (55% and 67%, respectively). Numerous other contextual factors associated with U5CM also improved over the evaluation period and likely contributed to declines in mortality. However, few of these factors contributed the same magnitude of mortality reduction as the combined malaria interventions. Our PAR% analysis illustrates how malaria control interventions contributed to the 45% decline in U5CM in Tanzania between 1999 and 2010, with 11% of this overall reduction attributable to ITNs alone. ITN use among Tanzanian children less than five years of age reached 64% by 2010, and further gains in child survival will be achieved with recent increases in ITN coverage.

After a decade (1990s) of stagnation in child survival in Tanzania, the decline in U5CM (1999–2010) was almost certainly a consequence of reductions in malaria-specific mortality associated with the 50% decline in SAP. The age and endemicity stratifications for SAP and mortality exhibited a pattern of change consistent and specific to observed malaria risk, with declines most pronounced in the more vulnerable children aged 1–23 months (6–23 months for SAP) in areas of higher malaria endemicity [42,64]. ITN coverage improved slowly between 2000 and 2007/8, and then increased abruptly by 2010. At time of the 2010 survey, children less than 24 months of age had benefited from this protection, helping to further accelerate mortality declines in this age group. While low IPTp coverage likely had only minimal impact.
on U5CM, these same pregnant women also benefited from access to ITN vouchers, resulting in increased protection for infants. Although no clear trend was observed in the proportion of children <5 years of age that received prompt treatment of fever with first-line antimalarials, substantial treatment efficacy had already been lost twice before national treatment policies transitioned. In 2000, chloroquine treatment failures by day 14 were 45% in Africa and as high as 71% in Tanzania [14] where 22 million malaria cases (confirmed or probable) were reported among children <5 years of age that year. A substantial number of these uncomplicated malaria cases treated with chloroquine likely experienced poor hematologic recovery which increased their risk of progression to severe malaria, an outcome associated with a 10–15% case-fatality rate, and up to 25–50% when accompanied by other severe sequelae [65,66]. Just five years later (2005) and only three years after SP replaced chloroquine, SP failure was 40% by day 14 [67]. Before SP was replaced with ACT as first-line treatment in 2007, some proportion of Tanzania’s annual 14–18 million uncomplicated malaria cases treated with SP during 2004–6 likely progressed to severe malaria with high case-fatality. Artemether-lumefantrine (mainland Tanzania’s first-line ACT) presently remains a highly efficacious treatment in Tanzania [68].

UNICEF estimates U5CM in Africa declined 20% between 2000 and 2010 (from 159 to 127 deaths per 1000 live births), with over one million children’s lives saved due to malaria interventions [4,69]. Recent national and sub-national analyses are more consistent with the higher reductions presented in this report. Zambia reduced U5CM 36% between 2001/2 and 2007, while severe anemia and parasitemia prevalence declined 68% and 53%, respectively, following rapid scale-up of malaria interventions [70]. U5CM in Rwanda declined 50% (from 152 to 76 deaths per 1000 live births) between 2001–5 and 2006–10, mostly following scale-up ITNs and ACTs [71]. On Bioko Island after four years of intervention scale-up (2005–08), U5CM declined 64% (from 152 to 55 deaths per 1000 live births) and SAP declined 86% (from 15% to 2%) [72]. Zanzibar, part of the Republic of Tanzania, achieved high intervention coverage earlier than the mainland and U5CM declined 52% between 2002 and 2005 [73]. A recent analysis from two districts in Tanzania detected a 43% decline in all-cause mortality among children 1–5 years of age between 1997 and 2009, with malaria interventions associated with the observed decline [74]. Our results are consistent with these published findings.

The United Nations Inter-Agency Group for Child Mortality Estimation (IGME) and the Institute for Health Metrics and Evaluation (IHME) have both derived Tanzania-specific estimates of U5CM. The decline in U5CM between 2000 and 2010 based on IGME estimates was 42% (132 to 76 deaths per 1000 live births) [69,75], quite comparable to the 45% decline in this report. However, IHME estimates correspond to a decline in U5CM of only 23% (127 to 98 deaths per 1000 live births) [76]. The IHME mortality estimates did not include 2010 Tanzania DHS data, thus the IHME modelled estimates likely over-estimated U5CM for 2010. In 2010 the largest contributors to U5CM in Africa included perinatal causes (30%), pneumonia (14%), diarrheal diseases (11%), HIV/AIDS (4%), and malnutrition through synergy with prevalent infectious diseases (35%) [77]. With approximately 15% of U5CM in Africa caused by malaria in 2010 (down from over 20% in 2000) [78], we carefully considered over 30 other Tanzania-specific contextual factors (socioeconomic, biological, and environmental risks) in our plausibility assessment of alternative explanations for declines in U5CM. Others have shown limited or no declines in neonatal mortality rates in Africa for the period 2000–10 [76,79], and the same was observed in Tanzania. Low levels of maternal education are associated with higher rates of U5CM, and in many countries more than half of the recent reductions in child deaths are linked to improvements in female education [53,80,81]. A recent analysis showed that for each one year increase in education of reproductive-age women (as observed in Tanzania), U5CM decreased by 9.5% [53]. Likewise, a 1% annual increase in GDP per capita
is associated with 0.4–0.6% reduction in U5CM [82]. Tanzania’s GDP per capita increased 47% (from $297 to $438, current U.S. dollars) between 1999 and 2010 [83], one of the fastest growing economies in Africa [84]. This growth in GDP could potentially correspond to a 18–27% reduction in U5CM, or between one-third and one-half of the 45% overall decline in U5CM over the same period. Water, sanitation and hygiene indicators did not significantly change.

The single biggest improvement among the biological determinants of child health was percentage of children 6–59 months of age who received vitamin A supplementation in the past six months. This intervention can reduce U5CM by up to 20%, particularly in high-priority countries (such as Tanzania) [58,59]. Despite a nearly 5-fold increase in vitamin A coverage between 1999 and 2010, the prevalence of vitamin A deficiency (serum retinol <0.70 μmol/l) among Tanzanian children actually increased from 24% in 1997 [85] to 38% in 2010 [86]. Thus Tanzania had a severe public health problem of vitamin A deficiency (prevalence ≥20% among child < 5 years) throughout our evaluation period. Notably, WHO recommends a vitamin A coverage threshold of 70%, the minimal level at which a country can expect to observe meaningful reductions in child mortality. Tanzania had only reached supplementation of 60% by 2010, making large reductions in U5CM attributable to this intervention unlikely [32].

Pregnant women, their unborn fetuses, and newborns benefit from four or more antenatal care (ANC4+) visits [54]. Two doses of tetanus toxoid to protect against neonatal tetanus is one intervention provided at ANC [87]. During the evaluation period, pregnant women completing ANC4+ visits declined by 39% which may have increased neonatal mortality. However, sufficient cumulative dosage of tetanus toxoid remained high and thus did not account for accelerated declines in U5CM. Maternal survival has a dramatic impact on U5CM, but it is very difficult to measure and confidence intervals are often wide [88,89]. The 37% decline in the maternal mortality ratio between 2000 and 2010 (from 730 to 460) [90] likely accelerated the declines in U5CM through other biologic determinants we examined.

Malaria transmission is sensitive to temperature and rainfall, but the effect of these on malaria morbidity and mortality are not well delineated [91]. Temperature influences the extrinsic life-cycle of the parasite and may also modify vector or human behavior, all combining to affect the transmission dynamics of sporozoites [92]. While rainfall suitable for malaria transmission persisted in Tanzania throughout the evaluation period, it is unlikely that variations in rainfall significantly altered malaria transmission. Climatic variables alone did not predict malaria outcomes in other analyses from northeastern Tanzania [93,94].

Tanzania experienced changes in multiple indicators of childhood nutrition, an important determinant of U5CM. Exclusive breast feeding in the first six months of life is recommended by WHO and UNICEF to partially protect against diarrheal and acute respiratory illness and mortality. Supplementation of breast milk with other liquids and foods begins very early in Tanzania: nearly half of infants younger than 2–3 months receive supplements. Given the modest protective efficacy of exclusive breastfeeding versus partial or predominant breastfeeding [56,95], and the limited change in prevalence of exclusive breastfeeding in Tanzania over time, this practice likely accounted for only a small decline in U5CM. Stunting and underweight prevalence reflect shortness-for-age and low weight-for-age, respectively, and are indicators of chronic malnutrition. Models estimate that a 5% reduction in prevalence of underweight is associated with a 13% reduction in U5CM [96]. Wasting prevalence (low weight-for-height) can reflect a recent and severe event causing substantial weight loss, but this indicator did not change in Tanzania during the evaluation period. No significant improvement in immunization coverage was detected during the evaluation period with the exception of *Haemophilus influenza* type b (Hib), introduced in 2009. While Hib is a contributor of meningitis and pneumonia deaths among Tanzanian children under five, the rapid Hib vaccine coverage achieved
by 2010 (88%) is unlikely to have caused a decline in U5CM so soon after introduction (less than one year).

Among the 49.7 million HIV infections that occurred worldwide by 1999, 72% were in sub-Saharan Africa; as were 91% of child HIV infections and 94% of child AIDS deaths [97]. HIV prevalence in Tanzania was monitored through household surveys and ANC sentinel sites over our evaluation period. While HIV prevalence among adults declined over 30% between 1999 and 2010, prevalence did not significantly decline among women of reproductive age or pregnant women. Estimates of pediatric HIV/AIDS prevalence in Tanzania are not available, but in the absence of antiretroviral therapy, over 50% of HIV-infected infants progress to AIDS and die within 24 months [98]. As part of the global effort to eliminate new HIV infections in infants, Tanzania accomplished major improvements in the provision of preventive services and care and treatment for HIV/AIDS, particularly PMTCT coverage which reached the majority of HIV-exposed infants by 2010. While PMTCT scale-up has reduced U5CM in Africa [99], the scale-up of in Tanzania mostly occurred after 2007 and benefited a relatively small proportion of the population less than five years of age. The best estimate of the percentage of pediatric deaths in Tanzania due to HIV/AIDS during 2010 was 5%, down from 8% in 2000 [77].

Our approach was accompanied by multiple limitations. We were unable to include national-level malaria morbidity/mortality data from health facilities, resulting in analyses entirely dependent upon household survey data. Using parasitemia prevalence data from only the 2007/8 Malaria Indicator Survey likely resulted in misclassification of our malaria endemi city categories over time. However, since malaria intervention scale-up in Tanzania occurred at a national level, this exposure misclassification over time was likely non-differential and thus not disproportionately higher among children with anemia or those who died at a younger age. More recent reports from two distinct locations in Tanzania [100,101], while limited to only one or two villages, indicate major reductions in parasitemia over our same evaluation period. Health facility-based data would provide longitudinal and spatial changes in parasites and anemia, important outcomes in the causal pathway considered in this evaluation. While all-cause mortality data from household surveys have excellent representativeness [22], the principle limitation is the bias introduced to mortality estimates based solely upon birth histories reported by respondents [102]. A disadvantage of using U5CM is the lack of specificity for malaria deaths and the non-malarial causes must be accounted for through adequacy and plausibility assessments. Likewise, U5CM reflects no impact for older children and adults who also benefit from malaria control in Tanzania, particularly those living with HIV/AIDS [103]. Monitoring ITN, IPTp, and case management outcome indicators through household surveys has multiple limitations. Prior to the deployment of LLINs (with insecticide incorporated into netting material), insecticide was hopefully applied directly to bednets by the beneficiary. Inability of a survey respondent to correctly recall timing of net retreatments may have produced unreliable estimates of ITN coverage. An appropriately treated ITN or an LLIN with sufficient insecticidal content may still not protect a user due to excessive holes/tears in the net. The proportion of children less than five years of age who sleep under an ITN continues to be influenced by perceptions regarding seasonal variation in malaria transmission risk [104,105]. Since these surveys are often done during the dry season to facilitate field team mobility, ITN use for the rest of the year may be underestimated [106]. IPTp coverage may be unreliable stemming from the respondent’s inability to identify which drug was given or how many doses [107]. A final major limitation of these household surveys is the lack of contemporary exposure data for children who died within the period covered by the survey. ITN use (night before the survey), first-line treatment (past two weeks), and all contextual factors were assessed only for children who survived through the time of the survey visit, but are not assessed for child deaths in the
whole 5-year period preceding the survey. This limits the conventional epidemiologic analyses of individual-level exposure/outcome data and increased reliance upon a plausibility design [24].

Malaria case management (testing and treatment) indicators from household surveys are particularly problematic for examining trends over time [52]. Respondents’ recall of facility-level diagnostic testing and treatment may not be valid. A final limitation relates to Hb measurement and estimates of SAP. Hb concentration among African children is influenced by many determinants including age, sex, nutrition, infections, environment, and genetic factors [108]. While malaria interventions have been associated with a 60% reduction in the risk of moderate-to-severe anemia (Hb < 8 g/dL) [70], in most of Africa the leading cause of pediatric anemia is iron deficiency. Aside from age and malaria endemicity, our analyses did not examine other anemia causing exposures. Notably, among Tanzania children 6–59 months of age only 1.4% received an iron supplement within seven days preceding the 2010 DHS [32].

Continued progress in malaria intervention scale-up and impact on the malaria burden in Tanzania are further supported by the most recent 2012 Tanzania HIV/AIDS and Malaria Indicator Survey [39]. The national malaria prevalence estimate using RDTs declined to 10% in 2012, a 47% relative reduction from the national prevalence of 18% in 2007/8 (also RDT-based). One high burden region (Kagera) targeted for intensive malaria control efforts since 2007 experienced a decline in malaria prevalence from 41% in 2007/8 to 8% in 2012 (and SAP among children 6–59 months declined from 9.3% to 3.2%). Nationally, household ownership of at least one ITN was 91% in 2012, up from less than 40% in 2007/8. The 2012 survey did not include new estimates for U5CM, but SAP among children 6–59 and 6–23 months (5.6% and 7.8%, respectively) were not significantly different from 2010 estimates.

Conclusion

After no improvement in child survival during the 1990s, the 45% reduction in U5CM and 50% reduction in SAP following malaria intervention scale-up is a major public health achievement for Tanzania. This impact was more accelerated among younger children (<23 months of age) living in higher malaria endemicity areas, the very children with the greatest potential to gain health improvements following malaria intervention scale-up. While other factors also contributed to the observed declines in U5CM, the large proportion of decline plausibly attributable to malaria control efforts is noteworthy. The progress achieved in malaria control can reverse quickly in the absence of continued financial support and strong political will. To avoid a return to the intense perennial transmission conditions that prevailed for so long, sustained focus on and support for comprehensive programs to control malaria will be required in Tanzania and other African countries.

Supporting Information

S1 Appendix. International Research Institute for Climate and Society/Mailman School of Public Health, The Earth Institute, Columbia University. Development of climate analysis section for the President’s Malaria Initiative impact evaluation: reports for Ethiopia and Tanzania, August 2012.

(S1 Fig. Annual funding levels and source of malaria control effort (A) and number of commodities procured and distributed (B) in Mainland Tanzania, 2000–10. Footnote: ‘GoT’ = Government of Tanzania; PMI = U.S. President’s Malaria Initiative (TIF)
S2 Fig. Insecticide treated net (ITN) coverage (A), severe anemia (Hb < 8.0 g/dL) prevalence (B), and all-cause mortality among children under-five (C) stratified by background characteristics in Mainland Tanzania, 2004/5, 2007/8, and 2010. (TIF)

S3 Fig. Weighted anomaly of standardized precipitation (WASP) analysis for Tanzania comparing (A) baseline period (1995–99) and (B) malaria intervention scale-up years (2000–10). Footnote: red indicates drier, green indicates wetter (compared to baseline) (TIF)

Acknowledgments

The following colleagues from the Tanzania Malaria Impact Evaluation Research Group contributed to this work: Yazoume Ye, Fred Arnold, Trevor Croft (ICF Macro, Calverton, Maryland); Angelica Rugarabamu, Salim Abdulla (Ifakara Health Institute, United Republic of Tanzania); Joanna Schellenberg (London School of Hygiene and Tropical Medicine, London, United Kingdom); Monica Olewe (MACEPA); Aly Mohammed, Renata Mandike, Fabrizio Molteni (National Malaria Control Programme, Ministry of Health and Social Welfare, Dar es Salaam, United Republic of Tanzania); Aldegunda Komba (National Bureau of Statistics, Dar es Salaam, United Republic of Tanzania); Rose Lusinde (RTI International, Dar es Salaam, United Republic of Tanzania); Chonge Kitojo, Naomi Kaspar, Jessica Kafuko (U.S. President’s Malaria Initiative—Dar es Salaam, United Republic of Tanzania); Ritha Njau (World Health Organization, Dar es Salaam, United Republic of Tanzania).

Author Contributions

Conceived and designed the experiments: PS LF AB AW PDM. Performed the experiments: PS LF PDM. Analyzed the data: PS LF HM PDM. Contributed reagents/materials/analysis tools: PS LF CLH HM. Wrote the paper: PS LF SRS CLH HM AB AM PDM.

References

1. Greenwood B, Koram K (2014) Malaria control in Africa: progress but still much to do. Lancet 383: 1703–1704. doi: 10.1016/S0140-6736(14)60044-1 PMID: 24559538
2. WHO (2013) World malaria report 2013. Geneva: World Health Organization.
3. Snow RW, Marsh K (2010) Malaria in Africa: progress and prospects in the decade since the Abuja Declaration. Lancet 376: 137–139. doi: 10.1016/S0140-6736(10)60577-6 PMID: 20417552
4. Roll Back Malaria Partnership (2011) A decade of partnership and results. Geneva: World Health Organization.
5. Roll Back Malaria Partnership (2008) Global malaria action plan. Geneva: World Health Organization.
6. Korenromp EL (2012) Lives saved from malaria prevention in Africa—evidence to sustain cost-effective gains. Malar J 11: 94. doi: 10.1186/1475-2875-11-94 PMID: 22455309
7. The Global Fund to Fight AIDS TaM (2010) Improving value for money in Global Fund supported programs. Geneva.
8. Lancet (2010) Evaluation: the top priority for global health. Lancet. 2010/01/19 ed. pp. 526.
9. Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, et al. (2009) A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 6: e1000048. doi: 10.1371/journal.pmed.1000048 PMID: 19323591
10. Omumbo JA, Hay SI, Snow RW, Tatem AJ, Rogers DJ (2005) Modelling malaria risk in East Africa at high-spatial resolution. Trop Med Int Health 10: 557–566. PMID: 15941419
11. National Malaria Control Programme (2003) Tanzania malaria medium-term strategic plan 2002–2007. Dar es Salaam: Tanzania Ministry of Health and Social Welfare.
12. National Malaria Control Programme (2008) Tanzania malaria medium-term strategic plan 2008–2013. Dar es Salaam: Tanzania Ministry of Health and Social Welfare.

13. Magesa SM, Lengeler C, deSavigny D, Miller JE, Njau RJ, et al. (2005) Creating an "enabling environment" for taking insecticide treated nets to national scale: the Tanzanian experience. Malar J 4: 34. PMID: 16042780

14. (EANMAT) TEANfMAT (2003) The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health 8: 860–867. PMID: 14516296

15. Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, et al. (2004) Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am J Trop Med Hyg 71: 696–702. PMID: 15642957

16. Mushi AK, Schellenberg JR, Mponda H, Lengeler C (2003) Targeted subsidy for malaria control with treated nets using a discount voucher system in Tanzania. Health Policy Plan 18: 163–171. PMID: 12740321

17. Hanson K, Nathan R, Marchant T, Mponda H, Jones C, et al. (2008) Vouchers for scaling up insecticide-treated nets in Tanzania: methods for monitoring and evaluation of a national health system intervention. BMC Public Health 8: 205. doi: 10.1186/1471-2458-8-205 PMID: 18544162

18. Bonner K, Mwita A, McElroy PD, Omari S, Mzava A, et al. (2011) Design, implementation and evaluation of a national campaign to distribute nine million free LLINs to children under five years of age in Tanzania. Malar J 10: 73. doi: 10.1186/1475-2875-10-73 PMID: 21453519

19. Renggli S, Mandike R, Kramer K, Patrick F, Brown NJ, et al. (2013) Design, implementation and evaluation of a national campaign to deliver 18 million free long-lasting insecticidal nets to uncovered sleeping spaces in Tanzania. Malar J 12: 85. doi: 10.1186/1475-2875-12-85 PMID: 23496881

20. Masanja H, de Savigny D, Smithson P, Schellenberg J, John T, et al. (2008) Child survival gains in Tanzania: analysis of data from demographic and health surveys. The Lancet 371: 1276–1283.

21. UNICEF (2013) Committing to child survival: a promise renewed. New York: UNICEF.

22. Rowe AK, Steketee RW, Arnold F, Wardlaw T, Basu S, et al. (2007) Viewpoint: evaluating the impact of malaria control efforts on mortality in sub-Saharan Africa. Trop Med Int Health 12: 1524–1539. PMID: 18076561

23. Rowe AK, Steketee RW (2007) Predictions of the impact of malaria control efforts on all-cause child mortality in sub-Saharan Africa. Am J Trop Med Hyg 77: 48–55. PMID: 18165474

24. Habicht JP, Victora CG, Vaughan JP (1999) Evaluation designs for adequacy, plausibility and probability of public health programme performance and impact. Int J Epidemiol 28: 10–18. PMID: 10195658

25. Bhutta ZA, Ahmed T, Black RE, Cousens S, Dewey K, et al. (2008) What works? Interventions for maternal and child undernutrition and survival. Lancet 371: 417–440. doi: 10.1016/S0140-6736(07)61693-6 PMID: 18206226

26. Calis JC, Phiri KS, Faragheh EB, Brabin BJ, Bates I, et al. (2008) Severe anemia in Malawian children. N Engl J Med 358: 888–899. doi: 10.1056/NEJMoa072727 PMID: 18305266

27. Victora CG, Habicht JP, Bryce J (2004) Evidence-based public health: moving beyond randomized trials. Am J Public Health 94: 400–405. PMID: 14998803

28. Hill A (1965) The environment and disease: association or causation? Proceedings of the Royal Society of Medicine 58: 295–300. PMID: 14283879

29. National Bureau of Statistics and Macro International (2000) Tanzania reproductive and child health survey 1999. Calverton, Maryland: National Bureau of Statistics and Macro International Inc.

30. National Bureau of Statistics and ORC Macro (2005) Tanzania demographic and health survey 2004–05. Dar es Salaam, Tanzania: National Bureau of Statistics and ORC Macro

31. Tanzania Commission for AIDS (TACAIDS) ZAC, National Bureau of Statistics (NBS), Office of Chief Government Statistician (OCGS), and Macro International, (2008) Tanzania HIV/AIDS and malaria indicator survey 2007–08. Dar es Salaam, Tanzania: TACAID, ZAC, NBS, OCGS, and Macro International Inc.

32. National Bureau of Statistics (NBS) and ICF Macro (2011) Tanzania demographic and health survey 2010. Dar es Salaam, Tanzania: NBS and ICF Macro.

33. Roll Back Malaria Partnership (2009) Guidelines for core population-based indicators. Geneva: The RBM Partnership.

34. MEASURE DHS/ICF International (2006) Guide to DHS statistics. Calverton, Maryland: ORC Macro.
35. Korenromp EL, Armstrong-Schellenberg JR, Williams BG, Nahlen BL, Snow RW (2004) Impact of malaria control on childhood anaemia in Africa—a quantitative review. Trop Med Int Health 9: 1050–1065. PMID: 15482397

36. International Monetary Fund (2012) EconStats: World Economic Outlook data.

37. UNAIDS (2012) Global report: UNAIDS report on the global AIDS epidemic 2012. Geneva: UNAIDS.

38. Tanzania Commission for AIDS (TACAIDS) NBoSN, and ORC Macro. (2005) Tanzania HIV/AIDS indicator survey 2003–04. Calverton, Maryland: TACAIDS, NBS, and ORC Macro.

39. Tanzania Commission for AIDS (TACAIDS) ZAC, National Bureau of Statistics (NBS), Office of Chief Government Statistician (OCGS), and ICF International. (2013) Tanzania HIV/AIDS and malaria indicator survey 2011–12. Dar es Salaam, Tanzania: TACAIDS, ZAC, NBS, OCGS, ICF International.

40. Inc. NBoSAM (1993) Tanzania demographic and health survey 1991/1992. Calverton, Maryland: National Bureau of Statistics and Macro International Inc.

41. Inc. NBoSAM (1997) Tanzania demographic and health survey 1996. Calverton, Maryland: National Bureau of Statistics and Macro International Inc.

42. Reyburn H, Mbatia R, Drakeley C, Bruce J, Carneiro I, et al. (2005) Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA 293: 1461–1470. PMID: 15784869

43. O’Meara WP, Mwangi TW, Williams TN, McKenzie FE, Snow RW, et al. (2008) Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg 79: 185–191. PMID: 18689622

44. Okiro EA, Al-Taiar A, Reyburn H, Idro R, Hodgson A, et al. (2007) Patterns of age-specific mortality in children in endemic areas of sub-Saharan Africa. Am J Trop Med Hyg 77: 99–105. PMID: 18165480

45. Lyon BA (2005) ENSO and the spatial extent of interannual precipitation extremes in tropical land areas. Journal of Climate 18: 5095–5109.

46. International Research Institute (2013) Weighted anomaly of standardized precipitation (WASP) analyses from the IRS.

47. Lengeler C (2000) Insecticide-treated bednets and curtains for preventing malaria. Cochrane Database Syst Rev: CD000363.

48. Eisele TP, Larsen DA, Anglewicz PA, Yukich J, Keating J, et al. (2012) Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa. Lancet Infect Dis 12: 942–949. doi: 10.1016/S1473-3099(12)70222-0 PMID: 22995852

49. Thwing J, Eisele TP, Steketee RW (2011) Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool. BMC Public Health 11 Suppl 3: S14. doi: 10.1186/1471-2458-11-S3-S14 PMID: 21501431

50. Gakidou E, Cowling K, Lozano R, Murray CJ (2010) Increased educational attainment and its effect on child mortality in 175 countries between 1970 and 2009: a systematic analysis. Lancet 376: 959–974. doi: 10.1016/S0140-6736(10)61257-3 PMID: 20851260
57. McDonald CM, Olofin I, Flaxman S, Fawzi WW, Spiegelman D, et al. (2013) The effect of multiple anthropometric deficits on child mortality: meta-analysis of individual data in 10 prospective studies from developing countries. Am J Clin Nutr 97: 896–901. doi: 10.3945/ajcn.112.047639 PMID: 23426036

58. Imdad A, Yakooob MY, Sudfeld C, Haider BA, Black RE, et al. (2011) Impact of vitamin A supplementation on infant and childhood mortality. BMC Public Health 11 Suppl 3: S20. doi: 10.1186/1471-2458-11-S3-S20 PMID: 21501438

59. Mayo-Wilson E, Imdad A, Herzer K, Yakooob MY, Bhutta ZA (2011) Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis. BMJ 343: d5094. doi: 10.1136/bmj.d5094 PMID: 21868478

60. Kelsey JL T W, Evans AS (1995) Public health methods—attributable risk as a link between causality and public health action. Am J Public Health 85: 1202–1204. PMID: 7661224

61. Hill GB (1996) The value of the population attributable risk percentage. Am J Public Health 86: 1483. PMID: 8876530

62. Lim SS, Fullman N, Stokes A, Ravishankar N, Masiye F, et al. (2011) Net benefits: a multicountry analysis of observational data examining associations between insecticide-treated mosquito nets and health outcomes. PLoS Med 8: e1001091. doi: 10.1371/journal.pmed.1001091 PMID: 21909249

63. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, et al. (1993) Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 167: 932–937. PMID: 8450258

64. Obonyo CO, Vulule J, Akhwale WS, Grobbee DE (2007) In-hospital morbidity and mortality due to severe malarial anemia in western Kenya. Am J Trop Med Hyg 77: 23–28. PMID: 18165471

65. Joseph D, Kabanywanyi AM, Hulser R, Premji Z, Minzi OM, et al. (2013) Exploration of in vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in under fives in Tabora region, Tanzania. Malar J 12: 60. doi:10.1186/1475-2875-12-60 PMID: 23397982

66. United Nations Inter-agency Group for Child Mortality Estimation (2011) Levels and trends in child mortality 2013. New York, NY: United Nations Children’s Fund.

67. Chizema-Kawesha E, Miller J, Steketee R, Mukonka V, Mukuka C, et al. (2010) Scaling up malaria control in Zambia: progress and impact 2005–2008. Am J Trop Med Hyg 83: 480–488. doi: 10.4269/ ajtmh.2010.10-0035 PMID: 20810807

68. Kleinschmidt I, Schwabe C, Benavente L, Torrez M, Riell FC, et al. (2009) Marked increase in child survival after four years of intensive malaria control. Am J Trop Med Hyg 80: 882–888. PMID: 19478243

69. Liu L, Johnson HL, Cousens S, Perin J, Scott S, et al. (2012) Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379: 2151–2161. doi:10.1016/S0140-6736(12)60560-1 PMID: 22579125
78. Black RE, Morris SS, Bryce J (2003) Where and why are 10 million children dying every year? Lancet 361: 2226–2234. PMID: 12842379
79. Lawn JE, Kinney MV, Black RE, Pitt C, Cousens S, et al. (2012) Newborn survival: a multi-country analysis of a decade of change. Health Policy Plan 27 Suppl 3: iii6–28. doi: 10.1093/heapol/czs053 PMID: 22692417
80. Basu AM, Stephenson R (2005) Low levels of maternal education and the proximate determinants of childhood mortality: a little learning is not a dangerous thing. Soc Sci Med 60: 2011–2023. PMID: 15743650
81. Cleland JG, Van Ginneken JK (1988) Maternal education and child survival in developing countries: the search for pathways of influence. Soc Sci Med 27: 1357–1368. PMID: 3070762
82. Filmer D, Pritchett L (1999) The impact of public spending on health: does money matter? Soc Sci Med 49: 1309–1323. PMID: 10509822
83. World Bank (2013) GDP per capita (current U.S. dollars).
84. International Monetary Fund (2011) Regional economic outlook: sub-Saharan Africa, recovery and new risks. Washington, DC: International Monetary Fund.
85. WHO (2009) Global prevalence of vitamin A deficiency in populations at risk 1995–2005. WHO global database on vitamin A deficiency. Geneva.
86. Macro NBoSnAl (2011) Micronutrients: Results of the 2010 Tanzania Demographic and Health Survey. Dar es Salaam, Tanzania.
87. Blencowe H, Lawn J, Vandelae J, Roper M, Cousens S (2010) Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int J Epidemiol 39 Suppl 1: i102–109. doi: 10.1093/ije/dyq027 PMID: 20348112
88. WHO Regional Office for Africa (2006) The health of the people: the African regional health report. Geneva: World Health Organization.
89. Yazbeck AS (2007) Challenges in measuring maternal mortality. Lancet 370: 1291–1292. PMID: 17933633
90. WHO, UNFPA, World Bank, (2012) Trends in maternal mortality 1990 to 2010. Geneva: World Health Organization.
91. Stresman GH (2010) Beyond temperature and precipitation: ecological risk factors that modify malaria transmission. Acta Trop 116: 167–172. doi: 10.1016/j.actatropica.2010.08.005 PMID: 20727338
92. Paaijmans KP, Read AF, Thomas MB (2009) Understanding the link between malaria risk and climate. Proc Natl Acad Sci U S A 106: 13844–13849. doi: 10.1073/pnas.0903423106 PMID: 19666598
93. Drakeley CJ, Carneiro I, Reyburn H, Malima R, Lusingu JP, et al. (2005) Altitude-dependent and -independent variations in Plasmodium falciparum prevalence in northeastern Tanzania. J Infect Dis 191: 1589–1598. PMID: 15838785
94. Gething PW, Smith DL, Patil AP, Tatem AJ, Snow RW, et al. (2010) Climate change and the global malaria recession. Nature 465: 342–345. doi: 10.1038/nature09098 PMID: 20485344
95. Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, et al. (2008) Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 371: 243–260. doi: 10.1016/S0140-6736(07)61690-0 PMID: 18207566
96. Pelletier DL, Frongillo EA Jr, Schroder DG, Habicht JP (1995) The effects of malnutrition on child mortality in developing countries. Bull World Health Organ 73: 443–448. PMID: 7554015
97. UNAIDS (1999) AIDS epidemic update. Geneva: UNAIDS.
98. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillardi P, et al. (2004) Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364: 1236–1243. PMID: 15464184
99. Govender T, Coovadia H (2014) Eliminating mother to child transmission of HIV-1 and keeping mothers alive: recent progress. J Infect 68 Suppl 1: S57–62. doi: 10.1016/j.jinf.2013.09.015 PMID: 24139190
100. Ishengoma DS, Mmbando BP, Segeja MD, Alifrangis M, Lemnge MM, et al. (2013) Declining burden of malaria over two decades in a rural community of Muheza district, north-eastern Tanzania. Malar J 12: 338. doi: 10.1186/1475-2875-12-338 PMID: 24083121
101. Pamert A, Yman V, Homann MV, Wandell G, Mhoja L, et al. (2014) Epidemiology of malaria in a village in the Rufiji River Delta, Tanzania: declining transmission over 25 years revealed by different parasitological metrics. Malar J 13: 459. doi: 10.1186/1475-2875-13-459 PMID: 25423887
102. Boerma JT, Sommerfelt AE (1993) Demographic and health surveys (DHS): contributions and limitations. World Health Stat Q 46: 222–226. PMID: 8017081
103. Cuadros DF, Branscum AJ, Crowley PH (2011) HIV-malaria co-infection: effects of malaria on the prevalence of HIV in East sub-Saharan Africa. Int J Epidemiol 40: 931–939. doi: 10.1093/ije/dyq256 PMID: 21224274

104. Atieli HE, Zhou G, Afrane Y, Lee MC, Mwanzo I, et al. (2011) Insecticide-treated net (ITN) ownership, usage, and malaria transmission in the highlands of western Kenya. Parasit Vectors 4: 113. doi: 10.1186/1756-3305-4-113 PMID: 21682919

105. Singh M, Brown G, Rogerson SJ (2013) Ownership and use of insecticide-treated nets during pregnancy in sub-Saharan Africa: a review. Malar J 12: 268. doi: 10.1186/1475-2875-12-268 PMID: 23914731

106. Pulford J, Hetzel MW, Bryant M, Siba PM, Mueller I (2011) Reported reasons for not using a mosquito net when one is available: a review of the published literature. Malar J 10: 83. doi: 10.1186/1475-2875-10-83 PMID: 21477376

107. Namusoke F, Ntale M, Wahlgren M, Kironde F, Mirembe F (2012) Validity of self-reported use of sulphadoxine-pyrimethamine intermittent presumptive treatment during pregnancy (IPTp): a cross-sectional study. Malar J 11: 310. PMID: 22950456

108. Abdalla SH P G (2011) Approach to the patient in the tropics with anemia. In: Guerrant RL W D, Weller PF, editor. Tropical Infectious Diseases: Principles, Pathogens & Practice. 3rd ed: Elsevier. pp. 1024–1032.

109. UNAIDS (2011) Global report: UNAIDS report on the global AIDS epidemic 2011. Geneva: Joint United Nations Programme on HIV/AIDS.

110. UNAIDS (2013) Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: Joint United Nations Programme on HIV/AIDS.